MINI ORALS 2026
Bladder & Urothelial Cancers
BK Virus Associated Urothelial Carcinoma – A Regional Cohort of Kidney Transplant Recipients
Bladder Cancer in Young Women: Clinicopathological Features and Risk Factors from a Multi-Center Retrospective Study
Sex Differences in Enfortumab Vedotin Efficacy and NECTIN-4 Levels in Metastatic Urothelial Cancer
First-Line or Maintenance Immune Checkpoint Inhibitors in Older Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Outcomes of Novel Systemic Therapies in Advanced Upper Tract Urothelial Carcinoma: A systematic Review and Meta-Analysis
‘STATE-OF-THE-NATION’ STUDY: UNDERSTANDING NHS TREATMENT PATHWAY TO ADVANCE HR NMIBC PATIENT CARE in the UK (SPAN UK)
Impact of delayed radical cystectomy following neoadjuvant chemotherapy on oncological outcomes in Muscle-invasive bladder cancer
Benchmarking Artificial Intelligence Based Clinical Prediction Models for Immune Checkpoint Inhibitor Response and Overall Survival in Bladder Cancer
Durvalumab + BCG therapy in BCG-naïve, high-risk NMIBC: efficacy and safety analyses from POTOMAC
Prostate Cancer
Prostate volume changes during longer fractionated and ultra-hypofractionated MR-guided adaptive radiotherapy leveraging the MOMENTUM registry
Challenges of AI in Surgical Planning for Radical Prostatectomy: Barriers and Progress
Real-world outcomes in patients with Metastatic Hormone-Sensitive Prostate Cancer treated with androgen deprivation therapy and Apalutamide – A single centre study
Assessment of QRISK®3 and Major Cardiovascular Events in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with ADT ± ARPI ± Docetaxel: A Retrospective Cohort Study
A pilot study of the implementation of the G8 frailty assessment in oncology clinics for patients with newly diagnosed metastatic hormone sensitive prostate cancer
Renal Cell Carcinoma
First‑line TKI, ipilimumab–nivolumab, and lenvatinib–pembrolizumab in metastatic non–clear cell RCC: real‑world survival across two UK centres
Real-world effectiveness of pembrolizumab plus axitinib in metastatic renal cell carcinoma in Panama
Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Evidence from an Immunotherapy-Inaccessible Cohort
Integrating Transcriptomic Profiles and Clinical Outcomes Across MEET-URO Risk Groups in Metastatic Renal Cell Carcinoma: A Comparative Analysis with the IMDC Framework
Sex-based Disparities in Metastatic Renal Cell Carcinoma: Real-World Data from Meet-URO33 Study.
Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations
Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC)
Adjuvant Pembrolizumab in RCC: Real world experience in Northern Ireland 2022-2026
Treatment beyond progression in primary refractory mRCC during 1L systemic therapy (Meet-Uro 33)
Impact of Metastatic Patterns on First-Line Therapy in mRCC: Meet-URO 33
Efficacy and tolerability of immune checkpoint inhibitors in older versus younger patients with metastatic renal cell carcinoma: a real-world Asian cohort
Synergistic potential of cabozantinib and radiotherapy in advanced renal cell carcinoma by site of irradiation
Cannabinoid Receptor Profiling Reveals a Low CB1 and High CB2 signature in Clear Cell Renal Cell Carcinoma
CHOLESTEROL HOMEOSTASIS AND IMMUNE-INFLAMMATORY PROFILES IN PATIENTS WITH mRCC RECEIVING IMMUNOTHERAPY
Stereotactic Body Radiotherapy and Immunotherapy for Metastatic Renal Cell Carcinoma Croatian Uro-Oncology Network Experience
Outcomes of dual immunotherapy versus other first line treatments for metastatic renal carcinoma
Testicular & Rare Cancers
De-escalated management of stage I seminoma: three decades of real-world outcomes
Clinical and Pathologic Outcomes of Resection of Thoracic Residual Masses in Germ Cell Tumors
Prostate Cancer UK – Education
Patient Voice & Sexual Wellbeing: In conversation with Steve Allen